First weight loss medication with an exclusive
low cash price available on the GoodRx platform
GoodRx (Nasdaq: GDRX), the leading prescription savings platform
in the U.S., announced today that QSYMIA® (phentermine and
topiramate extended-release capsules CIV) is available for a low
cash price in more than 70,000 retail pharmacy locations nationwide
exclusively via GoodRx. This initiative not only propels GoodRx’s
momentum in weight loss solutions, but also broadens its portfolio
in offering significant savings on brand-name medications, making
obesity treatment more accessible and affordable for millions.
According to the CDC, more than two in five U.S. adults have
obesity, and untreated obesity increases the risk of type 2
diabetes, hypertension, heart disease, and mortality. While demand
for weight-loss medications has soared in recent years, consumers
often struggle to access them due to high costs and lack of
insurance coverage. By making QSYMIA more accessible, GoodRx and
Vivus are helping those struggling with weight and obesity find
more affordable ways to access the treatments they need.
Now, anyone with a valid prescription, regardless of insurance
status, can use GoodRx to purchase a 30-day supply of QSYMIA at the
exclusive cash price of $149. QSYMIA is designed to help patients
manage hunger and reduce cravings throughout the day and, combined
with a healthy diet and exercise, has been proven to help patients
lose and maintain weight. Many individuals prefer oral medications
over injectables, and the simplicity of taking a daily pill can
make it easier to adhere to treatment regimens.
“Obesity medications are life-changing for millions of
Americans, but accessibility and affordability are often a barrier
for many consumers,” said Dorothy Gemmell, Chief Commercial Officer
at GoodRx. “Through this partnership, we’re making headway in
getting these critical medications into the hands of those who need
them and improving access to a medication that not only helps with
weight loss, but is also tied to better outcomes for other costly
chronic diseases.”
“We are dedicated to expanding access to our critical
medications that consumers rely on,” said John Amos, CEO at VIVUS.
“Collaborating with GoodRx enables us to offer an affordable
solution for individuals who have prescriptions for QSYMIA and
expand access to those seeking a cost-effective option to fill
them. One in five adults and one in four young adults (12-17)
experience weight loss on the top dose of QSYMIA of at least 20% of
their body weight. Our partnership with GoodRx coupled with the
weight loss profile of QSYMIA offers Americans an unprecedented
value vs. other therapies.”
GoodRx works with nearly 150 brands across pharmaceutical
manufacturers, medical device companies and OTC medicines to
surface their savings and patient support programs directly with
high-intent audiences via the GoodRx platform. The company recently
announced a partnership with Pfizer to offer its menopause hormone
therapies at low prices in retail pharmacies exclusively via
GoodRx. Similarly, the company launched an affordability program
with ARS Pharmaceuticals to offer neffy at an exclusive low
discounted cash price in retail pharmacies across the U.S.
About GoodRx
GoodRx is the leading prescription savings platform in the U.S.
Trusted by more than 25 million consumers and 750,000 healthcare
professionals annually, GoodRx provides access to savings and
affordability options for generic and brand-name medications at
more than 70,000 pharmacies nationwide, as well as comprehensive
healthcare research and information. Since 2011, GoodRx has helped
consumers save over $75 billion on the cost of their
prescriptions.
GoodRx periodically posts information that may be important to
investors on its investor relations website at
https://investors.goodrx.com. We intend to use our website as a
means of disclosing material nonpublic information and for
complying with our disclosure obligations under Regulation FD.
Accordingly, investors and potential investors are encouraged to
consult GoodRx’s website regularly for important information, in
addition to following GoodRx’s press releases, filings with the
Securities and Exchange Commission (the “SEC”) and public
conference calls and webcasts. The information contained on, or
that may be accessed through, GoodRx’s website is not incorporated
by reference into, and is not a part of, this press release.
About VIVUS
VIVUS is a biopharmaceutical company committed to the
development and commercialization of innovative therapies that
focus on advancing treatments for patients with serious unmet
medical needs. For more information about the Company, please visit
http://www.vivus.com.
About QSYMIA
QSYMIA is indicated in combination with a reduced-calorie diet
and increased physical activity to reduce excess body weight and
maintain weight reduction long term in adults and pediatric
patients aged 12 years and older with obesity, and in adults with
overweight in the presence of at least one weight-related comorbid
condition.
The effect of QSYMIA on cardiovascular morbidity and mortality
has not been established. The safety and effectiveness of QSYMIA in
combination with other products intended for weight loss, including
prescription drugs, over-the-counter drugs, and herbal
preparations, have not been established.
For more information on QSYMIA, please visit
https://QSYMIA.com/
Important Safety Information for QSYMIA
Do not take QSYMIA if you are pregnant, planning to become
pregnant, or become pregnant during QSYMIA treatment; have
glaucoma; have thyroid problems (hyperthyroidism); are taking
certain medicines called monoamine oxidase inhibitors (MAOIs) or
have taken MAOIs in the past 14 days; are allergic to topiramate,
sympathomimetic amines such as phentermine, or any of the
ingredients in QSYMIA.
QSYMIA can cause serious side effects, including birth defects
(cleft lip/cleft palate), serious eye problems (secondary angle
closure glaucoma), visual field defects (independent of elevated
intraocular pressure), suicidal thoughts or actions, and severe
rash with blisters and peeling skin. QSYMIA may slow the increase
in height in children 12 years and older.
Common side effects of QSYMIA in adults include numbness or
tingling in the hands, arms, feet, or face (paraesthesia),
dizziness, changes in the way foods taste or loss of taste
(dysgeusia), trouble sleeping (insomnia), constipation, and dry
mouth. Common side effects of Qsymia in children aged 12 years and
older include depression, dizziness, joint pain, fever, flu, and
ankle sprain.
For more information please read the Qsymia Medication Guide,
Full Prescribing Information, and Risk of Birth Defects with Qsymia
patient brochure.
GoodRx Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. All statements contained in this press release that do not
relate to matters of historical fact should be considered
forward-looking statements, including, without limitation,
statements regarding anticipated consumer savings and
accessibility; and the objectives and potential benefits and value
of the GoodRx and Vivus partnership. These statements are neither
promises nor guarantees, but involve known and unknown risks,
uncertainties and other important factors that may cause GoodRx’s
actual results, performance or achievements to be materially
different from any future results, performance or achievements
expressed or implied by the forward-looking statements, including,
but not limited to, risks relating to GoodRx’s ability to achieve
broad market education and change consumer purchasing habits,
changes in medication pricing and pricing structures, GoodRx’s
reliance on a limited number of industry participants, and the
important factors discussed in the section entitled “Risk Factors”
in GoodRx’s Annual Report on Form 10-K for the year ended December
31, 2023, and GoodRx’s other filings with the Securities and
Exchange Commission. Any such forward-looking statements are based
on current expectations, projections and estimates as of the date
of this press release. While GoodRx may elect to update such
forward-looking statements at some point in the future, GoodRx
disclaims any obligation to do so, even if subsequent events cause
GoodRx’s views to change.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20241029836195/en/
Press Contacts GoodRx press@goodrx.com
GoodRx (NASDAQ:GDRX)
Graphique Historique de l'Action
De Nov 2024 à Déc 2024
GoodRx (NASDAQ:GDRX)
Graphique Historique de l'Action
De Déc 2023 à Déc 2024
